Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system
- PMID: 22018880
- DOI: 10.1016/j.lungcan.2011.09.012
Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system
Abstract
Cachexia is a prevalent phenomenon of non-small cell lung cancer (NSCLC) which is responsible for increased mortality and deterioration of physical performance. Preclinical research indicates that systemic inflammation induces cachexia-related muscle wasting through muscular Nuclear Factor-kappa B (NF-κB) signaling and subsequent ubiquitin proteasome system (UPS)-mediated proteolysis. As these pathways could be a target for early intervention strategies, it needs to be elucidated whether increased activation of these pathways is already present in early stage NSCLC cachexia. The aim of the present study was therefore to assess muscular NF-κB and UPS activation in patients with NSCLC pre-cachexia. Sixteen patients with newly diagnosed stages I-III NSCLC having <10% weight loss and ten healthy controls were studied. Body composition, systemic inflammation and exercise capacity were assessed in all subjects and NF-κB and UPS activity in vastus lateralis muscle biopsies in a subset. Patients showed increased plasma levels of C-reactive protein (CRP) (P<0.001), soluble Tumor Necrosis Factor receptor 1 (sTNF-R1) (P<0.05), fibrinogen (P<0.001) and decreased levels of albumin (P<0.001). No changes in fat free body mass or skeletal muscle NF-κB and UPS activity were observed, while peak oxygen consumption ( [Formula: see text] ) was significantly decreased in patients compared with healthy controls. In conclusion, this exploratory study demonstrates significantly reduced exercise capacity in NSCLC pre-cachexia despite maintenance of muscle mass and unaltered indices of UPS activation. The absence of muscular NF-κB-dependent inflammatory signaling supports the notion that transition of systemic to local inflammation is required to initiate UPS-dependent muscle wasting characteristic for (experimental) cachexia.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Consequences of Late-Stage Non-Small-Cell Lung Cancer Cachexia on Muscle Metabolic Processes.Clin Lung Cancer. 2017 Jan;18(1):e1-e11. doi: 10.1016/j.cllc.2016.06.003. Epub 2016 Jun 25. Clin Lung Cancer. 2017. PMID: 27461772
-
Nuclear transcription factor κ B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia.Am J Clin Nutr. 2013 Sep;98(3):738-48. doi: 10.3945/ajcn.113.058388. Epub 2013 Jul 31. Am J Clin Nutr. 2013. PMID: 23902785
-
Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia.Oncol Rep. 2005 Jul;14(1):257-63. Oncol Rep. 2005. PMID: 15944798
-
Mechanisms of skeletal muscle atrophy.Curr Opin Rheumatol. 2006 Nov;18(6):631-5. doi: 10.1097/01.bor.0000245731.25383.de. Curr Opin Rheumatol. 2006. PMID: 17053511 Review.
-
The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting.J Support Oncol. 2005 May-Jun;3(3):209-17. J Support Oncol. 2005. PMID: 15915823 Review.
Cited by
-
LATS2 inhibits the activity of NF-κ B signaling by disrupting the interaction between TAK1 and IKKβ.Tumour Biol. 2015 Sep;36(10):7873-9. doi: 10.1007/s13277-015-3362-x. Epub 2015 May 7. Tumour Biol. 2015. PMID: 25946971
-
Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.Cancer. 2022 Aug 15;128(16):3067-3079. doi: 10.1002/cncr.34348. Epub 2022 Jun 21. Cancer. 2022. PMID: 35727053 Free PMC article. Clinical Trial.
-
Physical exercise at the crossroad between muscle wasting and the immune system: implications for lung cancer cachexia.J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):55-67. doi: 10.1002/jcsm.12900. Epub 2022 Jan 10. J Cachexia Sarcopenia Muscle. 2022. PMID: 35014216 Free PMC article. Review.
-
Concurrent evolution of cancer cachexia and heart failure: bilateral effects exist.J Cachexia Sarcopenia Muscle. 2014 Jun;5(2):95-104. doi: 10.1007/s13539-014-0137-y. Epub 2014 Mar 14. J Cachexia Sarcopenia Muscle. 2014. PMID: 24627226 Free PMC article.
-
Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know?J Cachexia Sarcopenia Muscle. 2020 Dec;11(6):1413-1428. doi: 10.1002/jcsm.12633. Epub 2020 Oct 14. J Cachexia Sarcopenia Muscle. 2020. PMID: 33053604 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous